Trial reportBritish journal of cancer2003
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Trial report in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00442507 (A Phase II Trial of Erlotinib and Avastin in Previously Treated Patients With Cancer of the Esophagus or Gastroesophageal Junction), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Trial of Erlotinib and Avastin in Previously Treated Patients With Cancer of the Esophagus or Gastroesophageal Junction
Who cites it
25 citing papers in PubMed, 74 citations in OpenAlex.
- Long-term outcome of PDT for local failure after CRT or RT for oesophageal cancer.Journal of gastroenterology · 2026Trial
- A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11).The oncologist · 2021Trial
- Trial
- Trial
- Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2009Trial
- Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2009Trial
- Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.Investigational new drugs · 2008Trial
- A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.Digestive diseases and sciences · 2005Trial
- Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.British journal of cancer · 2005Trial
- Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1.Esophagus : official journal of the Japan Esophageal Society · 2023Article
- Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report.Journal of medical case reports · 2022Article
- Optimum multi-drug regime for compartment model of tumour: cell-cycle-specific dynamics in the presence of resistance.Journal of pharmacokinetics and pharmacodynamics · 2021Article
- Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2019Article
- Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma.Thoracic cancer · 2016Article
- Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy.Oncology research · 2016Article
- Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma.Therapeutic advances in gastroenterology · 2015Review
- Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma.OncoTargets and therapy · 2014Article
- New and emerging combination therapies for esophageal cancer.Cancer management and research · 2013Article
- Phase I study of photodynamic therapy using talaporfin sodium and diode laser for local failure after chemoradiotherapy for esophageal cancer.Radiation oncology (London, England) · 2012Article
- Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?World journal of gastroenterology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This phase II trial assessed the toxicity and efficacy of irinotecan plus docetaxel in cisplatin-pretreated oesophageal cancer. Irinotecan 160 mg m(-2) plus docetaxel 65 mg m(-2) once every 3 weeks led to severe myelosuppression in four patients, all of whom experienced neutropenic fever. After amendment of this regimen, 24 patients (male/female=18/6; median age=58.5 years; ECOG performance status 0/1/2=9/11/4) with advanced oesophageal cancer (adenocarcinoma/epidermoid carcinoma=13/11) received irinotecan 55 mg m(-2) plus docetaxel 25 mg m(-2) on days 1, 8 and 15 of a 28-day cycle. Serious adverse events occurred in five patients, one with lethal outcome (pneumonia). Haematological toxicity >or=3 degrees was rare, whereas nonhaematological toxicity >or=3 degrees was noted in nine out of 24 patients (asthenia in five patients, diarrhoea in three patients, nausea/emesis in two patients, constipation in one patient). Median survival time was 26 (range 2-70) weeks. Response rate, assessed according to the WHO criteria, was 12.5% (95% CI 2.7-32.4%); rate of disease stabilisation (partial remission and stable disease) was 33.3% (95% CI 15.6-55.3%) with a median duration of 18.5 (range 16-51) weeks. Although the nonhaematological toxicity proved to be considerable, weekly irinotecan plus docetaxel is feasible and shows some activity in extensively pretreated patients with oesophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.